Back to News & Events

Anti-Cancer Agent Developed at SBU Shows Great Promise Against Tumors, Receives $24M Investment

A second-generation taxane conjugate in a nanoemulsion formulation (called NE-DHA-SBT-1214) developed by Stony Brook University Distinguished Professor Iwao Ojima in his chemistry laboratory and through the Institute of Chemical Biology & Drug Discovery (ICB&DD) and licensed to Dr. James Egan, has received a $24 million investment to be taken to phase 2a development. Preclinical results have persuaded TVM Capital Life Science to invest in the technology via Recurv Pharma.

The VC fund will invest up to $24 million in Recurv through its project-focused company (PFC) investment objective, an initiative focused on backing first or best-in-class candidates that are clearly differentiated from the competition or add clinical value. Read More on Fierce Pharma and via SBU News.

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => all
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 5031
                    [post_author] => 3
                    [post_date] => 2026-08-10 12:17:19
                    [post_date_gmt] => 2026-08-10 16:17:19
                    [post_content] => 

Attention Stony Brook University Faculy and Staff: Applications for the second cycle of the President’s Fast Impact Fund (FIF) opened August 3, 2026. Open to all Stony Brook faculty and staff, this special initiative supports immediate-impact projects that can be launched quickly and deliver results within six to ten months.

The FIF provides awards of up to $300,000 focused on low‑investment, high‑reward initiatives that create visible, positive change. Examples of projects that would be considered include specialized equipment or technology acquisitions, pilot programs or proof‑of‑concept initiatives, targeted renovations or seed funding, among other opportunities.

All proposals must include a customized, high-level budget and be endorsed by the relevant vice president or dean with authority to implement the project. Applications for the August cycle will be available beginning August 3 with submissions due Friday, August 21 by 5 pm, ET. Please visit the Fast Impact Fund website for additional information and to submit an application.

[post_title] => SBU President’s Fast Impact Fund (FIF) [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => sbu-presidents-fast-impact-fund-fif [to_ping] => [pinged] => [post_modified] => 2026-08-19 08:30:44 [post_modified_gmt] => 2026-08-19 12:30:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=5031 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 2210 [post_author] => 3 [post_date] => 2016-05-12 19:03:22 [post_date_gmt] => 2016-05-12 19:03:22 [post_content] => TheraSource LLC, a Feinstein Institute for Medical Research spin-out, has received a $3 million three-year Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH). The grant will support the development of human ghrelin as an innovative treatment to alleviate health damage caused by unintentional radiation exposure. TheraSource has been a client of the Center for Biotechnology and the organization is proud to have played an integral role in the helping the company advance their business and technology strategy. As noted by Diane Fabel, Director of Operations for the Center for Biotechnology, “The Phase II award for TheraSource is a significant landmark for the company and an important milestone for the region.” Ping Wang, MD, founder of TheraSource and Chief of Scientific Officer (CSO) of the Feinstein Institute has stated “Human ghrelin has been investigated in clinical trials of other indications.  With our new findings, we will soon be able to file an Investigational New Drug application to US Food and Drug Administration,” said Dr. Wang. “TheraSource has received investments to fund its various projects and is seeking strategic partnerships towards the goal of clinical development and commercialization.” For more details, read the company’s press release here. [post_title] => TheraSource LLC receives $3M SBIR Grant [post_excerpt] => TheraSource LLC, a Feinstein Institute for Medical Research spin-out, has received a $3 million three-year Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH). [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => therasource-llc-receives-3m-sbir-grant [to_ping] => [pinged] => [post_modified] => 2016-05-12 19:13:45 [post_modified_gmt] => 2016-05-12 19:13:45 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2210 [menu_order] => 181 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 3939 [post_author] => 4 [post_date] => 2022-10-10 18:44:46 [post_date_gmt] => 2022-10-10 18:44:46 [post_content] =>

The first virtual Health Security Innovation Showcase is being held on October 18 from 12 pm – 5 pm EDT to learn about high impact life science startups being supported by BARDA partners, including, CARB-X, the BARDA Accelerator Network, and the BARDA-J&J Blue Knight program. These companies are developing platform technologies in a variety of technology areas, including diagnostic tools, therapeutics/vaccines, advanced manufacturing, and clinical trial support.

Highlights of the event:

- A Keynote address by Dr. Gary Disbrow, Director of BARDA
- 5-minute pitches by each company, followed by 3 minutes of Q&A
- Overviews of BARDA programs supporting innovation in the health security space
- Opportunities for you to set up one-on-one partnering meetings with the presenting companies

The event platform will contain company profiles, pitch decks and live calendars to be used to facilitate and set up meetings. Once registered, additional details will be provided on how to access and view the details of the participating companies.

Click here to register*

*When your registration request is approved, you will receive an email from the event system asking you to log in and fill out your profile.

[post_title] => Health Security Innovation Showcase - 10/18 [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => health-security-innovation-showcase-10-18 [to_ping] => [pinged] => [post_modified] => 2023-07-10 12:41:24 [post_modified_gmt] => 2023-07-10 16:41:24 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3939 [menu_order] => 17 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 4368 [post_author] => 4 [post_date] => 2024-01-18 12:28:20 [post_date_gmt] => 2024-01-18 17:28:20 [post_content] =>

The Center for Biotechnology on behalf of the Long Island Bioscience Hub is pleased to announce a request for proposals for our two-tiered technology development & commercialization program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo).  More information can be found thru this link (or view on CfB web-page)… 

Review the full funding program overview and proposal guidelines

Stony Brook University faculty and postdoctoral associates, alone or in partnership with companies or CFB-appointed BioEntrepreneurs-in-Residence (BEIRs), are eligible to apply. In all instances, the faculty member or post-doctoral associate must serve as the principal investigator, and the project must be executed on the academic campus at Stony Brook University.

Application Deadline: March 7, 2024 no later than 5pm.

Interested applicants are strongly recommended to connect with the Center for Biotechnology team before writing a full proposal and submission.  
Please contact Phuong Nguyen, PhD, at the Center for Biotechnology: phuong.t.nguyen@stonybrook.edu.

[post_title] => Funding Opportunity for SBU Researchers: Development and Commercialization of Bio-Based Technologies for Human Health  [post_excerpt] => We are pleased to announce a request for proposals for our two-tiered technology development & commercialization program open to SBU researchers. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => funding-opportunity-for-sbu-researchers-development-and-commercialization-of-bio-based-technologies-for-human-health [to_ping] => [pinged] => https://centerforbiotechnology.org/who-we-are/long-island-bioscience-hub/ [post_modified] => 2024-08-22 11:28:36 [post_modified_gmt] => 2024-08-22 15:28:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4368 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 5031 [post_author] => 3 [post_date] => 2026-08-10 12:17:19 [post_date_gmt] => 2026-08-10 16:17:19 [post_content] =>

Attention Stony Brook University Faculy and Staff: Applications for the second cycle of the President’s Fast Impact Fund (FIF) opened August 3, 2026. Open to all Stony Brook faculty and staff, this special initiative supports immediate-impact projects that can be launched quickly and deliver results within six to ten months.

The FIF provides awards of up to $300,000 focused on low‑investment, high‑reward initiatives that create visible, positive change. Examples of projects that would be considered include specialized equipment or technology acquisitions, pilot programs or proof‑of‑concept initiatives, targeted renovations or seed funding, among other opportunities.

All proposals must include a customized, high-level budget and be endorsed by the relevant vice president or dean with authority to implement the project. Applications for the August cycle will be available beginning August 3 with submissions due Friday, August 21 by 5 pm, ET. Please visit the Fast Impact Fund website for additional information and to submit an application.

[post_title] => SBU President’s Fast Impact Fund (FIF) [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => sbu-presidents-fast-impact-fund-fif [to_ping] => [pinged] => [post_modified] => 2026-08-19 08:30:44 [post_modified_gmt] => 2026-08-19 12:30:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=5031 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 284 [max_num_pages] => 95 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) [query_cache_key:WP_Query:private] => )

SBU President’s Fast Impact Fund (FIF)

More Information

TheraSource LLC receives $3M SBIR Grant

More Information

Health Security Innovation Showcase – 10/18

More Information

Funding Opportunity for SBU Researchers: Development and Commercialization of Bio-Based Technologies for Human Health 

More Information